FINCoVac 2.1
Nasal corona virus vaccine against rapidly mutating variants
Nasal corona virus vaccine against rapidly mutating variants
Research and product development
The aim of our company’s development work is to consolidate the use of new vaccine technology in Finland. At the heart of our product development is currently the second-generation coronavirus vaccine FINCoVac 2.1, which aims to obtain strong protection against the rapidly mutating variants of the coronavirus.
The mutation of the SARS-CoV-2 virus to evade the immune system is likely to continue at a rapid pace and new variant outbreaks may be expected. The FINCoVac 2.1 vaccine is designed to meet the challenge of the rapidly mutating variants. Our aim is that in the future, our vaccines could be an easy-to-dose booster for those who are already fully vaccinated with other coronavirus vaccine(s). The same vaccine technology can also enable the development of new vaccines against other viruses.
Clinical trials
Challenges in vaccine production have delayed the initiation of clinical trials, but now our first phase I trial has started. Healthy adult volunteers who are already fully vaccinated with other coronavirus vaccine(s), as well as a small group of volunteers previously unvaccinated against COVID-19, are invited to participate in the clinical trial. After Phase I clinical trial, the next broader trial, Phase II, will be commenced, depending on the results of the previous phase.